Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial

Abstract

BackgroundIn patients with systemic sclerosis (scleroderma, SSc), impaired hand function greatly contributes to disability and reduced quality of life, and is insufficiently relieved by currently available therapies. Adipose tissue-derived stromal vascular fraction (SVF) is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune diseases. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with SSc with hand disability.MethodsWe did an open-label, single arm, at one study site with 6-month follow-up among 12 female SSc patients with Cochin Hand Function Scale score >20/90. Autologous SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles. Primary outcome was the number and the severity of adverse events related to SVF-based therapy. Secondary endpoints were changes in hand disability and fibrosis, vascular manifestations, pain and quality of life from baseline to 2 and 6 months after cell therapy.FindingsAll enrolled patients had surgery, and there were no dropouts or patients lost to follow-up. No severe adverse events occurred during the procedure and follow-up. Four minor adverse events were reported and resolved spontaneously. A significant improvement in hand disability and pain, Raynaud's phenomenon, finger oedema and quality of life was observed.InterpretationThis study outlines the safety of the autologous SVF cells injection in the hands of patients with SSc. Preliminary assessments at 6 months suggest potential efficacy needing confirmation in a randomised placebo-controlled trial on a larger population.FundingGFRS (Groupe Francophone de Recherche sur la Sclérodermie).Clinical Trials numberNCT01813279.

Myeloid Progenitors: A Radiation Countermeasure that is Effective when Initiated Days after Irradiation

“…For this indication, collection of cell samples and their expansion, transport, preparation, cryopreservation, shipment to site of use and subsequent injection have all been important considerations and are primary logistical challenges of their clinical use. Use of the ADRCs has also improved outcomes in patients with systemic sclerosis (53)(54)(55)(56) and improved healing of thermal burns (57). Cytori Therapeutics is developing ADRCs for thermal burn injury, including burns that are complicated by radiation exposure, and these ADRCs improved healing of full thickness burns in minipigs exposed to a sub-lethal dose of total body irradiation (TBI) -a radiation combined injury (58).…”

Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds

“…96 In 2013 an open-label and single arm study was performed in 12 SSc patients in order to evaluate the number of adverse events related to SVF injection. 97 This procedure improved manifestations of peripheral vasculitis as Raynaud's phenomenon, ameliorate digital ulcers and consequently had an impact on hand pain. These results suggest that SVF may improve vasomotor tone and microvascular perfusion.…”

Regenerative Medicine: Charting a New Course in Wound Healing

“…In addition to refinements in harvesting, processing, and delivering autologous keratinocytes, researchers are pursuing the use of autologous adipose-derived regenerative cells for the treatment of skin conditions such as scleroderma and chronic ulcers. 79,80 Adipose-derived stem cells have also been induced to differentiate into keratinocytelike cells that form a stratified epidermis. 81 Stem cells derived from hair follicles are another key area of interest due to their ability to differentiate into multiple skin cell types, including melanocytes, and the ease with which they can be harvested from patients.…”